Journal article
Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
T-Cells and Cancer, Experimental & Translational Immunology, Department of Health Technology, Technical University of Denmark1
Experimental & Translational Immunology, Department of Health Technology, Technical University of Denmark2
Department of Health Technology, Technical University of Denmark3
Universität Regensburg4
Chimeric antigen receptor (CAR) redirected T-cells has shown efficacy in the treatment of B-cell leukemia/lymphoma, however, high numbers of relapses occur due to loss of targeted antigen or intrinsic failure of the CAR T-cells. In this situation modifications of the basic strategy are envisaged to reduce the risk of relapse, some of them are in early clinical exploration.
These include simultaneous targeting of multiple antigens or combination of CAR T-cell therapy with other treatment modalities such as checkpoint inhibitors. The review evaluates and discusses these modified advanced therapies and pre-clinical approaches with respect to their potential to control leukemia and lymphoma in the long-term.
Language: | English |
---|---|
Publisher: | Springer Berlin Heidelberg |
Year: | 2022 |
Pages: | 2301-2311 |
ISSN: | 14320851 and 03407004 |
Types: | Journal article |
DOI: | 10.1007/s00262-022-03163-y |
ORCIDs: | Ormhøj, Maria and Hadrup, Sine R. |